Future Leaders | 2019

26th Annual Future Leaders in the Biotech Industry

April 12, 2019 | New York City

The Future Leaders Class of 2019 will showcase the Next Wave of investment opportunities in redefining disease, expanding the world of druggable targets, advancing next-generation modalities and applying AI to drug development.

Road show presentations, 1x1 meetings and VIP networking enable these independently selected biotech pathfinders to engage with the most active Wall Street investors, analysts and business development execs in the life science space. In 2018, the Future Leaders audience controlled more than $500 billion in equity assets, including $10 billion devoted to biotech.

In a single day, the Future Leaders Class of 2019 will give investors key insights into the direction of the biotech universe and how Future Leaders CEOs are charting the way forward in new, sometimes unchartered territories.

Matching Innovators with Investors

Use the Future Leaders 1x1 meeting system to plan your day and arrange face-to-face executive level discussions.

  • Build a personalized conference schedule
  • Arrange 1x1 meetings
  • Access BCIQ Company Profiles to preview the Presenting Companies (BCIQ Profiles can be accessed by clicking the Company logo under Presenters)

Return to Conferences List
Friday, April 12, 2019

7:30 AM  to  8:50 AM
Registration and Buffet Breakfast
Millennium Broadway Hotel & Conference Center
8:50 AM  to  9:00 AM
Welcome & Introductions
Room - 402 / 403
Welcome & Introductions
Room - 404 / 405

9:00 AM  to  9:30 AM
Redhill Biopharma Ltd. (NASDAQ:RDHL; Tel Aviv:RDHL)
Room - 402 / 403
Late-stage therapies for GI diseases; cancer
Ophthotech Corp. (NASDAQ:OPHT)
Room - 404 / 405
New modalities to treat retinal diseases

9:30 AM  to  10:00 AM
Caladrius Biosciences Inc. (NASDAQ:CLBS)
Room - 402 / 403
Cell therapies for cardiovascular disease, autoimmunity
Pear Therapeutics Inc.
Room - 404 / 405
Digital prescription therapeutics

10:00 AM  to  10:15 AM
Aro Biotherapeutics Co.
Room - 402 / 403
Centyrin platform for multi-target delivery
10:00 AM  to  10:30 AM
Expansion Therapeutics Inc.
Room - 404 / 405
RNA-binding small molecules for cancer
10:15 AM  to  10:30 AM
Auransa Inc.
Room - 402 / 403
AI-based discovery for personalized medicine
10:30 AM  to  10:45 AM
Northern Biologics Inc.
Room - 402 / 403
New immunotherapy targets in the tumor microenvironment
10:30 AM  to  11:00 AM
Refuge Biotechnologies Inc.
Room - 404 / 405
Genetic engineering of immune cells
10:45 AM  to  11:00 AM
Pionyr Immunotherapeutics Inc.
Room - 402 / 403
Target discovery in the tumor microenvironment
11:00 AM  to  11:30 AM
Black Diamond Therapeutics Inc.
Room - 402 / 403
Targeting allosteric mutations in oncogenes
11:00 AM  to  11:15 AM
Jnana Therapeutics Inc.
Room - 404 / 405
Targeting transporters for IBD
11:15 AM  to  11:30 AM
Kymera Therapeutics Inc.
Room - 404 / 405
Protein degradation for oncology, autoimmunity
11:15 AM  to  12:00 PM
Hot Topic Breakout
Room - 411
Why VCs & Pharma Entrepreneurs Are Building Hot Topic Companies
Biotech is set to deliver on the biggest wave of product innovation since it solved the antibody riddle. Now VCs and pharma entrepreneurs are putting even bigger bets on deep biology and digital science to deliver the next transformations. But how should the Street be evaluating these opportunities? In this breakout session with BioCentury’s David Flores, newco creators share their views on risk and reward as these new stories reach the capital markets.

• Susan Dillon, Ph.D., Co-Founder, President & CEO, Aro Biotherapeutics; former Global Therapeutic Area Head, Immunology, Janssen

• Kevin Forrest, Ph.D., Co-Founder, President & CEO, Expansion Therapeutics; formerly 5AM Ventures

• William Ho, Co-Founder, President & CEO, Incysus Therapeutics and Managing Partner, AlephPoint Capital; formerly New Leaf Venture Partners; Bank of America; Piper Jaffray

• Derrick Li, Head of Strategy & Investor Relations, Cellular Biomedicine Group and Co-Founder, TPP Healthcare; formerly Managing Director Healthcare Investment Banking, B. Riley Financial

• Philip Vickers, Ph.D., CEO, Northern Biologics; former Global Head of R&D, Shire Pharmaceuticals
11:30 AM  to  12:00 PM
BlackThorn Therapeutics Inc.
Room - 402 / 403
Targeted treatments for neurobehavior
11:30 AM  to  11:45 AM
Maverick Therapeutics Inc.
Room - 404 / 405
Bispecific T-cell engagers for solid tumors
11:45 AM  to  12:00 PM
Accent Therapeutics Inc.
Room - 404 / 405
RNA epigenetics for cancer
12:00 PM  to  1:30 PM
Lunch with the Companies
8th Floor
1:30 PM  to  2:00 PM
Innovative Cellular Therapeutics Co. Ltd.
Room - 402 / 403
CAR T cells for blood and solid cancers
Clinuvel Pharmaceuticals Ltd. (ASX:CUV; Pink:CLVLY)
Room - 404 / 405
PDUFA, photomedicines for orphan skin disorders

1:30 PM  to  2:15 PM
Hot Topic Breakout
Room - 411
Redefining Disease & Expanding the Druggable Universe
The new generation of biotechs are combining biological insights, novel technologies and digital science to change how we define a disease and to attack targets that have been beyond reach until now. The challenge is to explain these innovations to the capital markets. In this breakout session with BioCentury’s Simone Fishburn, Ph.D., scientist-entrepreneurs lay out how they plan to translate their discoveries into value for investors as well as patients.

• Robert Copeland, Ph.D., Co-Founder, President & CSO, Accent Therapeutics

• Matthew Disney, Ph.D., Scientific Founder, Expansion Therapeutics

• Joanne Kotz, Ph.D., Co-Founder, President & CEO, Jnana Therapeutics

• Pek Lum, Ph.D., Co-Founder & CEO, Auransa

• Yochi Slonim, Co-Founder & CEO, Anima Biotech
2:00 PM  to  2:30 PM
Eutilogics Inc.
Room - 402 / 403
T cell therapies for lymphoma; solid cancers
Terns Pharmaceuticals Inc.
Room - 404 / 405
Treating NASH in China, US and EU

2:30 PM  to  3:00 PM
Adastra Pharmaceuticals Inc.
Room - 402 / 403
Blocking myc in glioblastoma and liver cancer
2:30 PM  to  2:45 PM
Incysus Therapeutics Inc.
Room - 404 / 405
Gamma-delta T cells for off-the-shelf cell therapy
2:45 PM  to  3:00 PM
Landos Biopharma Inc.
Room - 404 / 405
Oral therapeutics for autoimmune disease
3:00 PM  to  3:30 PM
Vaccinex Inc. (NASDAQ:VCNX)
Room - 402 / 403
Targeted therapies in neurodegeneration, cancer, autoimmunity
BioXcel Therapeutics Inc. (NASDAQ:BTAI)
Room - 404 / 405
AI to identify new indications for existing products

3:30 PM  to  4:00 PM
Cellular Biomedicine Group Inc. (NASDAQ:CBMG)
Room - 402 / 403
Cell therapies for cancer, regenerative medicine
3:30 PM  to  3:45 PM
Nuritas Ltd.
Room - 404 / 405
AI platform to find bioactive peptides
3:45 PM  to  4:00 PM
Anima Biotech Inc.
Room - 404 / 405
Controlling mRNA translation
4:00 PM  to  4:15 PM
Araim Pharmaceuticals Inc.
Room - 404 / 405
Tissue repair to treat chronic diseases

The Presenting Companies

The Future Leaders Class of 2019 has been hand-picked by BioCentury based on rigorous selection criteria, including innovative science and technology, investor validation, upcoming milestones and unpartnered assets.

After more than 25 years, the Street recognizes Future Leaders as the best independent venue for top-tier investors, analysts and investment professionals to assess the next wave of biotech leadership.

For information on becoming a Presenting Company, please email Eric Pierce.

The Initial Slate

  • Accent Therapeutics Inc.
  • Adastra Pharmaceuticals Inc.
  • Anima Biotech Inc.
  • Araim Pharmaceuticals Inc.
  • Aro Biotherapeutics Co.
  • Auransa Inc.
  • BioXcel Therapeutics Inc.
  • Black Diamond Therapeutics Inc.
  • BlackThorn Therapeutics Inc.
  • Caladrius Biosciences
  • Clinuvel
  • Expansion Therapeutics
  • Eutilogics Inc.
  • Incysus Therapeutics Inc.
  • Innovative Cellular Therapeutics Co. Ltd.
  • Jnana Therapeutics Inc.
  • Kymera Therapeutics Inc.
  • Landos Biopharma
  • Maverick Therapeutics Inc.
  • Northern Biologics
  • Nuritas Ltd.
  • Ophthotech Corp.
  • Pear Therapeutics
  • Pionyr Immunotherapeutics Inc.
  • Redhill Biopharma Ltd.
  • Refuge Biotechnologies Inc.
  • Terns Pharma
  • Vaccinex Inc.

BioCentury pioneered the "turf-neutral" concept on Wall Street, creating an open door for all members of the financial community to do business with independently selected Presenting Companies.

This approach has been possible because of the durable support of our Sponsors, whose endorsements enable BioCentury to make this truly "A Collaborative Gathering of the Corporate and Investment Communities."

For information on becoming a sponsor, please email Eric Pierce.


  • {title}
  • {title}
  • {title}